Breaking News Instant updates and real-time market news.

TELL

Tellurian

$5.55

0.33 (6.32%)

, BYND

Beyond Meat

$168.75

4.43 (2.70%)

08:45
08/13/19
08/13
08:45
08/13/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Tellurian (TELL) 30.45% +2.45, Beyond Meat (BYND) 56.33% +1.29, AngloGold (AU) 1.51% +1.22, Uxin Ltd (UXIN) 34.14% +1.11, Maxar Technologies (MAXR) 4.58% +0.69, Community Health (CYH) 1.45% +0.66, Karyopharm (KPTI) 1.11% +0.22, Inseego (INSG) 13.30% +0.16, iShares Hong Kong (EWH) 0.67% +0.15, and ProShares UltraShort S&P 500 (SDS) 0.81% +0.14.

TELL

Tellurian

$5.55

0.33 (6.32%)

BYND

Beyond Meat

$168.75

4.43 (2.70%)

AU

AngloGold

$20.10

-0.14 (-0.69%)

UXIN

Uxin

$2.49

-0.015 (-0.60%)

MAXR

Maxar Technologies

$7.40

-0.41 (-5.25%)

CYH

Community Health

$2.17

-0.275 (-11.27%)

KPTI

Karyopharm

$8.74

-0.11 (-1.24%)

INSG

Inseego

$4.11

-0.225 (-5.20%)

EWH

MSCI Hong Kong Index

$22.50

-0.72 (-3.10%)

SDS

UltraShort S&P500 ProShares

$31.82

0.75 (2.41%)

  • 14

    Aug

  • 14

    Aug

  • 28

    Aug

TELL Tellurian
$5.55

0.33 (6.32%)

05/13/19
GABE
05/13/19
INITIATION
GABE
Buy
Tellurian initiated with a Buy at Gabelli
Gabelli analyst Matthew Trusz started Tellurian with a Buy rating and $14 private market value estimate. The analyst views the company's equity-partnership model as unique to the U.S. market, and says it is further differentiated by its willingness to take commodity price risk.
03/12/19
03/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with an Overweight at Consumer Edge. 2. Crinetics (CRNX) initiated with an Overweight at Cantor Fitzgerald. 3. Tellurian (TELL) initiated with a Buy at BTIG. 4. Stealth Biotherapeutics (MITO) initiated with an Outperform at Evercore ISI, a Buy at Nomura Instinet, and a Hold at Jefferies. 5. Resideo (REZI) initiated with an Outperform at Imperial Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/16/19
STFL
07/16/19
DOWNGRADE
STFL
Hold
Tellurian downgraded to Hold from Buy at Stifel
Stifel analyst Benjamin Nolan downgraded Tellurian to Hold from Buy and lowered his price target on shares to $9 from $16. The analyst said he sees growth in LNG production limiting gas price upside, and pointed out that lower gas prices longer term would "have a negative impact on Tellurian's marketing margins and consequently their discounted cash flows." Nolan concluded that with a "dampened view on LNG prices," he no longer believes the shares offer "a risk/reward worth taking."
07/18/19
STFL
07/18/19
NO CHANGE
Target $9
STFL
Hold
Tellurian higher after Stifel issues 'Mea Culpa' on share count calculation
Shares of Tellurian (TELL) are higher in afternoon trading following a note issued before the open by a Stifel analyst who corrected a prior mistake he found in his calculations when having downgraded the stock earlier this week. In a note titled "Mea Culpa on TELL Share Count," analyst Benjamin Nolan acknowledged that in his downgrade published on July 16 he had an error in his calculation of the proposed private equity component of Tellurian's capital structure. After correcting his prior mistake, Nolan said there would be more potential upside should the company get to Final Investment Decision, or FID, on phase 1 of the Driftwood LNG project. He raised his "fully baked" discounted cash flow value estimate to $36 per share from $26 per share given the correction, though Nolan maintains a Hold rating and $9 price target on Tellurian shares. The stock is up 31c, or 4.7%, to $6.98 in afternoon trading.
BYND Beyond Meat
$168.75

4.43 (2.70%)

07/02/19
FBCO
07/02/19
NO CHANGE
Target $125
FBCO
Neutral
Credit Suisse boosts Beyond Meat sales estimates but keeps $125 price target
To account for "strong" retail sales growth in his Nielsen tracking data and continued distribution gains at new restaurant chains, Credit Suisse analyst Robert Moskow raised his fiscal 2020 and 2021 revenue estimates for Beyond Meat to $360M and $511M from $350M and $472M, respectively. The analyst also boosted his EBITDA estimates for Beyond Meat modestly above consensus. Moskow, however, keeps a Neutral rating on the shares with an unchanged price target of $125. The stock closed Monday down $8.10, of 5%, to $152.58. The analyst now expects 64M of shares outstanding in 2020, up from 60M, due to dilution from option grants. The $125 price target assumes a multiple in-line with other early-stage technologically driven growth stocks in the consumer space, discounted back to current value, Moskow tells investors in a research note.
06/13/19
FBCO
06/13/19
NO CHANGE
FBCO
Tyson plant-based launch not big threat to Beyond Meat, says Credit Suisse
Credit Suisse analyst Robert Moskow says this morning's launch of plant-based chicken nuggets and patties and hybrid beef-plant burgers and sausages supports his positive view on Tyson Foods (TSN). Perdue and Hormel Foods (HRL) have also signaled similar intentions to pursue hybrid meats, Moskow tells investors in a research note. The analyst, however, does not view Tyson's hybrid burgers as a major threat to Beyond Meat (BYND). Beyond's burger products are "more revolutionary and broader" in terms of potential consumer appeal, contends Moskow. Although competing hybrid burgers offer less saturated fat than the 100% plant-based products from Beyond and Impossible, "they simply don't taste as good in our experience," writes the analyst. Shares of Beyond Meat are down $1.04 to $140.93 in early trading while Tyson Foods is up $1.92 to $83.82.
06/12/19
06/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Cisco (CSCO) downgraded to Market Perform from Outperform at William Blair with analyst Jason Ader saying he sees "signs of tightening demand" across IT infrastructure, which he believes could pressure growth in Cisco's fiscal 2020, "especially when compared against unusually strong demand in fiscal 2019." 2. Manpower (MAN) downgraded to Neutral from Outperform at Credit Suisse. 3. Dave & Buster's (PLAY) downgraded to Hold from Buy at Gordon Haskett and SunTrust, as well as to Market Perform from Outperform at Wells Fargo. 4. Amcor (AMCR) reinstated with a Sell from Neutral at Goldman Sachs with analyst Brian Maguire saying Bemis's earnings growth "has not proven to be as resilient in recent years." 5. Beyond Meat (BYND) downgraded to Market Perform from Outperform at Bernstein with analyst Alexia Howard saying "valuation considerations as the stock has traded in a highly volatile manner since its IPO likely due to its limited public float." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/12/19
BERN
06/12/19
DOWNGRADE
Target $123
BERN
Market Perform
Beyond Meat downgraded to Market Perform from Outperform at Bernstein
Bernstein analyst Alexia Howard downgraded Beyond Meat to Market Perform from Outperform with a price target of $123. . The downgrade is due to "valuation considerations as the stock has traded in a highly volatile manner since its IPO likely due to its limited public float," Howard tells investors in a research note. The analyst now sees limited upside for the stock. Beyond Meat closed yesterday down 25%, or $42.06, to $126.04 after JPMorgan analyst Ken Goldman downgraded the shares on valuation concerns
AU AngloGold
$20.10

-0.14 (-0.69%)

06/27/19
BMOC
06/27/19
UPGRADE
Target $21
BMOC
Outperform
AngloGold upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Andrew Kaip upgraded AngloGold Ashanti to Outperform from Market Perform and raised his price target for the shares to $21 from $16. The company has a "solid record of delivery" and is tracking well towards delivering Obuasi by year-end, Kaip tells investors in a research note. AngloGold is one of the better large gold producers for exposure to a rising gold price, adds the analyst. The upgrade coincides with BMO's more constructive outlook for gold.
06/26/19
RBCM
06/26/19
DOWNGRADE
RBCM
Sector Perform
Gold Fields running 'well ahead' of peers in last 3 months, says RBC Capital
RBC Capital analyst James Bell downgraded Gold Fields (GFI) to Sector Perform from Outperform, telling investors in a research note that while the company's two-year reinvestment plan is paying off, the stock has run "well ahead" of its peers in the last three months. The analyst recommends a rotation into peer AngloGold (AU), which he upgraded to Outperform. The Gold Fields story is delivering against expectations, Bell says, but there are less catalysts from here than AngloGold, Bell says.
06/26/19
RBCM
06/26/19
UPGRADE
RBCM
Outperform
AngloGold upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital analyst James Bell upgraded AngloGold to Outperform from Sector Perform, telling investors in a research note that his caution has been addressed by CEO Dushinsky and his team with a clearer strategy now defined. Bell says while there are risks, they appear achievable and should deliver multiple near-term catalysts.
06/26/19
RBCM
06/26/19
UPGRADE
RBCM
Outperform
AngloGold upgraded to Outperform from Sector Perform at RBC Capital
UXIN Uxin
$2.49

-0.015 (-0.60%)

03/14/19
JPMS
03/14/19
NO CHANGE
Target $8
JPMS
Overweight
JPMorgan sees over 70% upside in Uxin, ups price target to $8
JPMorgan analyst Nick Lai raised his price target for Uxin to $8 from $7 following the company's better than expected Q4 results. The stock closed yesterday down 2c to $4.60. The analyst increased his revenue forecasts for 2019 and 2020 and believes Uxin will turn to profit in Q4 of 2019. For 2019, Lai forecasts intercity transaction will quadruple while believing same city should also surge by greater than 30%. He keeps an Overweight rating on Uxin shares.
04/16/19
04/16/19
NO CHANGE

Uxin exaggerates auto volumes by as much as 40%, says J Capital
J Capital Research analyst Anne Stevenson-Yang believes Uxin exaggerates the volume of auto sales its processes by as much as 40%. After speaking to dealers, former executives, and salespeople from competing companies, the analyst believes Uxin is "basically a Craigslist of autos," listing cars that are being offered on multiple websites, for free. Further, financial statements for Uxin's operating companies in China "show a staggering level of debt that puts the company at risk of collapse," Stevenson-Yang tells investors in a research note. She admits to not knowing how to ascribe a valuation to the stock since the company "is so dishonest." Investors should "race to the exits," says Stevenson-Yang. Uxin in early trading is up 1c to $3.06.
04/24/19
04/24/19
NO CHANGE

Uxin mentioned cautiously again by J Capital
J Capital Research has published a follow-up report on its short call on Uxin to respond to the company's response to the firm's April 16 short report. In the follow-up, J Capital's Anne Stevenson-Yang writes in part: "Uxin's response on the number of cities covered - it says 900 - contradicts what Investor Relations told us just one week before the report." Reference Link
03/12/19
FBCO
03/12/19
INITIATION
Target $7.7
FBCO
Outperform
Uxin initiated with an Outperform at Credit Suisse
Credit Suisse initiated Uxin with an Outperform and $7.70 price target.
MAXR Maxar Technologies
$7.40

-0.41 (-5.25%)

03/01/19
03/01/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. L Brands (LB) downgraded to Market Perform from Outperform at Bernstein with analyst Jamie Merriman saying her Outperform rating was based on a view that investors were paying for Bath & Body Works with a free option on Victoria's Secret. 2. American Airlines (AAL) and Delta Air Lines (DAL) downgraded to Hold from Buy at Deutsche Bank. 3. Devon Energy (DVN) downgraded to Sector Perform from Outperform at RBC Capital. 4. O'Reilly Automotive (ORLY) downgraded to Neutral from Overweight at Atlantic Equities with analyst Sam Hudson citing valuation and raised his price target to $400 from $370. 5. Maxar Technologies (MAXR) downgraded to Hold from Speculative Buy at TD Securities and to Underperformer from Neutral at CIBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/01/19
03/01/19
DOWNGRADE
Target $9

Hold
Maxar Technologies downgraded to Hold at TD Securities after disappointing Q4
As previously reported, TD Securities analyst Tim James downgraded Maxar Technologies to Hold from Speculative Buy and lowered his price target to $9 from $18.50 after its below-consensus Q4 results. The analyst says his previous constructive thesis attributing the company's weakness to the divestable GEO comsat business was incorrect as the company indicated it will continue to operate it at a loss. James added that the EBITDA of Maxar's Services and Imagery segment was also soft and recommends that investors await for evidence of improvement before considering buying shares again.
03/01/19
TDSI
03/01/19
DOWNGRADE
TDSI
Hold
Maxar Technologies downgraded to Hold from Speculative Buy at TD Securities
03/01/19
CIBC
03/01/19
DOWNGRADE
CIBC
Underperformer
Maxar Technologies downgraded to Underperformer from Neutral at CIBC
CYH Community Health
$2.17

-0.275 (-11.27%)

11/15/18
UBSW
11/15/18
INITIATION
UBSW
HCA Healthcare, Encompass Health, Universal Health initiated with Buy at UBS
UBS analyst Whit Mayo launched coverage of Healthcare Facilities with a broader research note titled "Navigating an Evolving Landscape - Who Will Be Left?". The analyst is most bullish on stocks that "discount the perceived secular sector headwinds" such as Buy-rated HCA Healthcare (HCA), Encompass Health (EHC), and Universal Health (UHS), adding that investors also under-appreciate the accelerating free-cash flow profiles of these companies. Mayo differentiates HCA Healthcare based on its 0% correlation in national hospital utilization trends against public results. The analyst is also bullish on LHC Group (LHCG), stating that its same-property admission growth projections are higher than the rest. Mayo rates Community Health Systems (CYH), DaVita (DVA), and Mednax (MD) at a Sell with a bearish view of dialysis, births, and inpatient surgery end-markets. The analyst sees Community Health Systems same-property volume trend at a relatively low rate. Mayo also gives Acadia (ACHC), Amedisys (AMED), Surgery Partners (SGRY), and Tenet (THC) a Neutral rating as part of this research note based on their relative valuation as a factor of same-property volume growth.
12/28/18
PIPR
12/28/18
NO CHANGE
PIPR
Piper says buy Centene, sell Community Health if recession were to occur
After performing a recession risk/reward for Hospitals and Managed Care Organizations, Piper Jaffray analyst Sarah James recommends buying Centene (CNC) and selling Community Health Systems (CYH) if a recession were to occur. The analyst says that with some economists calling for a recession in 2019, she dug into the potential impacts across the hospital and insurance sector. For hospitals, consumer surveys point to economic outlook impacting decisions to receive services, James tells investors in a research note. On the other hand, insurers are a "natural defensive sector in a recession," adds the analyst. As such, in a recession James would be adding exposure to insurers and lightening hospitals.
04/17/19
SPHN
04/17/19
NO CHANGE
SPHN
Issues facing healthcare sector now 'modest' compared to 2008-10, says Stephens
Stephens analyst Scott Fidel noted that the managed care group has sharply underperformed the S&P 500 over the last month amid "political rhetoric" around point-of-sale drug rebates and Medicare for all policy proposals, though he believes the issues facing the sector right now "seem modest in comparison" to the "dark days of 2008-2010." While recent Medicare for all proposals have rattled investors, "they will face enormous uphill battles," Fidel tells investors. Hospital stocks have outperformed MCOs year-to-date, but the group declined about 9% yesterday and underperformed the MCO group, which Fidel attributes to acknowledgement by industry bellwether UnitedHealth (UNH) of the significant disruptive nature of Medicare for all, which may have sparked additional fears, as well as one less calendar day being called out by UnitedHealth as benefiting Q1 MLRs and Johnson & Johnson's (JNJ) earnings call commentary on declining sequential hospital admissions from Q4. Publicly traded companies in the hospital space include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS). Publicly traded companies in the managed care space include Anthem (ANTM), CVS Health (CVS), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
07/10/19
GSCO
07/10/19
UPGRADE
Target $160
GSCO
Buy
Goldman upgrades HCA Healthcare to Buy, boosts priced target to $160
Goldman Sachs analyst Stephen Tanal upgraded HCA Healthcare (HCA) to Buy from Neutral and raised his price target for the shares to $160 from $147. After deep dive of local market competitive dynamics and market share patterns of hospitals, the analyst has a "greater appreciation for the resiliency" of the economic model of certain acute hospitals, notably HCA. The company, and certain other hospital systems, have sufficient bargaining power at the local level to mitigate the effects of any potential negative policy actions taken by government agencies, Tanal tells investors in a research note. The analyst keeps Sell ratings on both Community Health (CYH) and Universal Health (UHS).
KPTI Karyopharm
$8.74

-0.11 (-1.24%)

07/23/19
JPMS
07/23/19
UPGRADE
Target $16
JPMS
Overweight
Karyopharm upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Eric Joseph upgraded Karyopharm Therapeutics to Overweight from Neutral and doubled his price target for the shares to $16 from $8. The analyst says his doctor survey supports a "strong" Xpovio launch and long-term outlook.
07/23/19
07/23/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Buy from Hold at Stifel with analyst John Egbert saying the company's sales reorganization efforts were already reflected in its prior guidance and the daily active user checks for the quarter appear to be positive. 2. Murphy Oil (MUR) upgraded to Buy from Neutral at Goldman Sachs with analyst Brian Singer saying he believes the company's free cash flow generation is being underappreciated by the market. 3. Karyopharm (KPTI) upgraded to Overweight from Neutral at JPMorgan with analyst Eric Joseph saying he conducted a U.S. physician survey assessing Xpovio anticipated use in the approved indication of penta-refractory myeloma, as well as expectations around use in earlier-line settings. The survey of 15 doctors data show favorable reception to Xpovio's clinical profile, with 75% respondents intending to write Xpovio for PR-MM within the next 12 months. 4. Smith & Nephew (SNN) upgraded to Buy from Hold at Berenberg with analyst Tom Jones saying he believes management and process changes have addressed the company's execution issues. He views Smith & Nephew's portfolio as "highly competitive." 5. Columbia Sportswear (COLM) upgraded to Buy from Neutral at BofA/Merrill with analyst Alexander Perry citing his outlook for the company to generate "significant near-term revenue and EPS upside" amid a strong wholesale environment for Columbia's apparel as well as its "significant" under-penetration in footwear. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/23/19
JPMS
07/23/19
UPGRADE
Target $16
JPMS
Overweight
JPMorgan upgrades Karyopharm after doctor survey, doubles price target
JPMorgan analyst Eric Joseph upgraded Karyopharm Therapeutics to Overweight from Neutral and doubled his price target for the shares to $16 from $8. The analyst conducted a U.S. physician survey assessing Xpovio anticipated use in the approved indication of penta-refractory myeloma, as well as expectations around use in earlier-line settings. The survey of 15 doctors data show favorable reception to Xpovio's clinical profile, with 75% respondents intending to write Xpovio for PR-MM within the next 12 months, Joseph tells investors in a research note. Importantly, nearly all respondents described the side-effect profile as manageable, which is "very encouraging," adds the analyst. He sees a favorable reward/risk profile for Karyopharm shares at current levels.
07/05/19
WEDB
07/05/19
NO CHANGE
Target $11
WEDB
Outperform
Wedbush boosts Karyopharm target to $11 from $6 on Xpovio approval
Wedbush analyst David Nierengarten raised his price target for Karyopharm Therapeutics to $11 from $6 after the FDA on Wednesday approved selinexor, now branded as Xpovio, in combination with dexamethasone for the treatment of multiple myeloma in patients who have received at least four prior therapies. The stock closed Wednesday up 36% to $8.90. The label has no black box warnings or contraindications, but does include extensive safety monitoring guidelines and recommendations, Nierengarten tells investors in a research note. Karyopharm has priced Xpovio at $22,000 per month, which comes in higher than expected but is "not unreasonable" in comparison to other FDA-approved multiple myeloma drugs, contends the analyst. He projects sales of $9.1M in fiscal 2019, with peak sales potential approaching $300M. Nierengarten keeps an Outperform rating on Karyopharm Therapeutics.
INSG Inseego
$4.11

-0.225 (-5.20%)

05/24/19
05/24/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zoom Video (ZM) initiated with a Perform at Oppenheimer. 2. CannTrust (CTST) initiated with a Buy at BofA/Merrill. 3. Inseego (INSG) initiated with an Outperform at Cowen. 4. Falcon Minerals (FLMN) initiated with an Outperform at Baird. 5. Aphria (APHA) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/20/19
NATL
03/20/19
INITIATION
Target $6
NATL
Buy
Inseego initiated with a Buy at National Securities
National Securities analyst Matthew Galinko initiated Inseego (INSG) with a Buy rating and $6 price target, citing his view that its fundamentals, from product execution to go-to-market, are improving and that its recent wins with other carriers should help its concentration with Verizon (VZ) become less severe.
05/24/19
COWN
05/24/19
INITIATION
COWN
Outperform
Inseego initiated with an Outperform at Cowen
05/24/19
COWN
05/24/19
INITIATION
Target $8
COWN
Outperform
Inseego initiated with an Outperform, $8 target at Cowen
Cowen analyst Lance Vitanza started Inseego with an Outperform rating and $8 price target. The company has a strong position within the "burgeoning" 5G market, Vitanza tells investors in a research note. With an estimated 20% annual revenue growth over the next few years, the stock deserves a premium valuation, says the analyst. He sees a "multitude of multi-billion-dollar market segments" to which Inseego technology can serve.
EWH MSCI Hong Kong Index
$22.50

-0.72 (-3.10%)

SDS UltraShort S&P500 ProShares
$31.82

0.75 (2.41%)

TODAY'S FREE FLY STORIES

CMCSA

Comcast

$43.17

0.82 (1.94%)

, AEO

American Eagle

$15.40

0.63 (4.27%)

19:34
08/18/19
08/18
19:34
08/18/19
19:34
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

CMCSA

Comcast

$43.17

0.82 (1.94%)

AEO

American Eagle

$15.40

0.63 (4.27%)

MO

Altria Group

$46.48

1 (2.20%)

CMCSK

Comcast

$0.00

(0.00%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 04

    Sep

  • 25

    Sep

  • 25

    Sep

  • 27

    Oct

  • 13

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

19:27
08/18/19
08/18
19:27
08/18/19
19:27
Periodicals
Trump does not want to do business with Huawei, Reuters reports »

President Donald Trump…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XYF

X Financial

$2.61

0.04 (1.56%)

19:25
08/18/19
08/18
19:25
08/18/19
19:25
Earnings
X Financial reports Q2 EPS 31c, consensus 22c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

VJET

Voxeljet

$1.64

-0.05 (-2.96%)

18:44
08/18/19
08/18
18:44
08/18/19
18:44
Recommendations
Voxeljet analyst commentary at Piper Jaffray »

Voxeljet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

$0.00

(0.00%)

, AAPL

Apple

$206.44

4.71 (2.33%)

18:40
08/18/19
08/18
18:40
08/18/19
18:40
Periodicals
Apple CEO warns Trump about China tariffs, Reuters reports »

President Donald Trump…

SSNLF

Samsung

$0.00

(0.00%)

AAPL

Apple

$206.44

4.71 (2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

T

AT&T

$34.98

0.64 (1.86%)

, CMCSA

Comcast

$43.17

0.82 (1.94%)

18:05
08/18/19
08/18
18:05
08/18/19
18:05
On The Fly
Box Office Battle: 'Good Boys' wins weekend with $21M debut »

"Box Office Battle" is…

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$55.72

0.64 (1.16%)

LGF.A

Lionsgate

$11.06

0.02 (0.18%)

LGF.B

Lionsgate

$10.52

0.01 (0.10%)

DIS

Disney

$135.19

1.79 (1.34%)

VIAB

Viacom

$26.02

0.09 (0.35%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 23

    Oct

  • 27

    Oct

SFTBF

SoftBank

$0.00

(0.00%)

, SFTBY

SoftBank

$0.00

(0.00%)

17:59
08/18/19
08/18
17:59
08/18/19
17:59
Periodicals
Softbank plans to lend up to $20B to employees to invest in new fund, WSJ says »

Softbank is planning to…

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:50
08/18/19
08/18
16:50
08/18/19
16:50
Periodicals
Trump administration to give Huawei more time to work with U.S. clients,WSJ says »

The Trump administration…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JSAIY

J Sainsbury

$0.00

(0.00%)

16:46
08/18/19
08/18
16:46
08/18/19
16:46
Periodicals
J Sainsbury's not talking to internal candidates for CEO succession,Reuters says »

J Sainsbury's is not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$219.92

4.27 (1.98%)

16:39
08/18/19
08/18
16:39
08/18/19
16:39
Hot Stocks
Tesla relaunching solar-panel business with no-contract rentals »

Tesla is now offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:14
08/18/19
08/18
16:14
08/18/19
16:14
Periodicals
White House says no recession in sight, Reuters reports »

White House officials…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$89.46

0.91 (1.03%)

16:11
08/18/19
08/18
16:11
08/18/19
16:11
Periodicals
Novartis executive sold shares before data manipulation made public,Reuters says »

An unnamed Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

MO

Altria Group

$46.48

1 (2.20%)

16:08
08/18/19
08/18
16:08
08/18/19
16:08
Periodicals
CDC investigating lung illness linked to e-cigarette use, Reuters reports »

The Centers for Disease…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFB

CrossFirst Bancshares

$14.61

(0.00%)

, JFU

9F Inc

$10.09

0.52 (5.43%)

08:48
08/18/19
08/18
08:48
08/18/19
08:48
On The Fly
Opening Day: CrossFirst rises after setting IPO share price lower than expected »

Shares of CrossFirst…

CFB

CrossFirst Bancshares

$14.61

(0.00%)

JFU

9F Inc

$10.09

0.52 (5.43%)

NET

Cloudflare

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

SDC

SmileDirectClub

$0.00

(0.00%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

MSFT

Microsoft

$136.13

2.39 (1.79%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 27

    Oct

CBS

CBS

$43.83

0.5 (1.15%)

, VIA

Viacom

$27.27

-0.4 (-1.45%)

08:03
08/17/19
08/17
08:03
08/17/19
08:03
Periodicals
Viacom-CBS merger got panned by investors, Barron's says »

CBS (CBS) and Viacom…

CBS

CBS

$43.83

0.5 (1.15%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

VIAB

Viacom

$26.02

0.09 (0.35%)

AAPL

Apple

$206.44

4.71 (2.33%)

DIS

Disney

$135.19

1.79 (1.34%)

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

NFLX

Netflix

$302.74

6.81 (2.30%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

  • 27

    Oct

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

07:57
08/17/19
08/17
07:57
08/17/19
07:57
Periodicals
Myriad Genetics stock might have an FDA issue, Barron's says »

Myriad Genetics plunged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CSCO

Cisco

$46.96

0.73 (1.58%)

, NTAP

NetApp

$46.75

0.33 (0.71%)

07:50
08/17/19
08/17
07:50
08/17/19
07:50
Periodicals
Trade war hitting tech stocks, Barron's says »

Cisco (CSCO) plunged 9% a…

CSCO

Cisco

$46.96

0.73 (1.58%)

NTAP

NetApp

$46.75

0.33 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

  • 10

    Oct

  • 13

    Nov

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

, RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

07:47
08/17/19
08/17
07:47
08/17/19
07:47
Periodicals
Investors should not abandon oil, gas stocks, Barron's says »

Energy stocks have rarely…

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

CVX

Chevron

$115.79

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 25

    Sep

TGT

Target

$84.20

1.67 (2.02%)

, WMT

Walmart

$112.99

0.32 (0.28%)

07:40
08/17/19
08/17
07:40
08/17/19
07:40
Periodicals
Grocery Outlet thriving as rivals struggle, Barron's says »

While Dow was down 800…

TGT

Target

$84.20

1.67 (2.02%)

WMT

Walmart

$112.99

0.32 (0.28%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

AEO

American Eagle

$15.40

0.63 (4.27%)

07:33
08/17/19
08/17
07:33
08/17/19
07:33
Periodicals
American Eagle to soar despite trade war, Barron's says »

American Eagle's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 25

    Sep

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

, MTCH

Match Group

$84.53

2.08 (2.52%)

07:27
08/17/19
08/17
07:27
08/17/19
07:27
Periodicals
Dating business might be IAC's best asset, greatest challenge, Barron's says »

IAC (IAC) has rallied 34%…

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

MTCH

Match Group

$84.53

2.08 (2.52%)

IAC

IAC

$249.17

4.21 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 10

    Oct

AAPL

Apple

$206.44

4.71 (2.33%)

, HAS

Hasbro

$114.29

1.13 (1.00%)

07:13
08/17/19
08/17
07:13
08/17/19
07:13
On The Fly
Week in review How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$206.44

4.71 (2.33%)

HAS

Hasbro

$114.29

1.13 (1.00%)

MAT

Mattel

$10.74

(0.00%)

AGR

Avangrid

$49.29

0.37 (0.76%)

JPM

JPMorgan

$107.73

2.52 (2.40%)

BAC

Bank of America

$27.04

0.79 (3.01%)

C

Citi

$63.46

2.13 (3.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 27

    Oct

NCLH

Norwegian Cruise Line

$50.48

1.38 (2.81%)

18:04
08/16/19
08/16
18:04
08/16/19
18:04
Hot Stocks
Norwegian Cruise Line CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$27.12

0.14 (0.52%)

18:01
08/16/19
08/16
18:01
08/16/19
18:01
Hot Stocks
Regional Management CFO buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

RTN

Raytheon

$178.10

-0.42 (-0.24%)

17:59
08/16/19
08/16
17:59
08/16/19
17:59
Hot Stocks
Raytheon awarded $199.59M Navy contract for MK 15 CIWS »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.